This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MacCallum, D. M.
Right arrow Articles by Odds, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MacCallum, D. M.
Right arrow Articles by Odds, F. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4911-4914, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4911-4914.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Need for Early Antifungal Treatment Confirmed in Experimental Disseminated Candida albicans Infection

Donna M. MacCallum and Frank C. Odds*

Aberdeen Fungal Group, School of Medical Sciences, Institute of Medical Sciences, Aberdeen, United Kingdom

Received 14 May 2004/ Returned for modification 18 June 2004/ Accepted 8 August 2004

Groups of mice infected intravenously with Candida albicans were treated intraperitoneally with amphotericin B, caspofungin, or fluconazole, starting at intervals before and after challenge. Survival was longest and tissue burdens were most reduced with early treatment, and survival times fell proportionately as treatment was delayed, reinforcing clinical recommendations for the earliest possible initiation of antifungal therapy.


* Corresponding author. Mailing address: FRCPath, Aberdeen Fungal Group, Institute of Medical Sciences, Aberdeen AB25 2ZD, United Kingdom. Phone and fax: 44 1224 555828. E-mail: f.odds{at}abdn.ac.uk.


Antimicrobial Agents and Chemotherapy, December 2004, p. 4911-4914, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4911-4914.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Tavares, P. M., Thevissen, K., Cammue, B. P. A., Francois, I. E. J. A., Barreto-Bergter, E., Taborda, C. P., Marques, A. F., Rodrigues, M. L., Nimrichter, L. (2008). In Vitro Activity of the Antifungal Plant Defensin RsAFP2 against Candida Isolates and Its In Vivo Efficacy in Prophylactic Murine Models of Candidiasis. Antimicrob. Agents Chemother. 52: 4522-4525 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2008). Caspofungin Disk Diffusion Breakpoints and Quality Control. J. Clin. Microbiol. 46: 1927-1929 [Abstract] [Full Text]  
  • Hope, W. W., Drusano, G. L., Moore, C. B., Sharp, A., Louie, A., Walsh, T. J., Denning, D. W., Warn, P. A. (2007). Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis. Antimicrob. Agents Chemother. 51: 285-295 [Abstract] [Full Text]  
  • Warn, P. A., Sharp, A., Mosquera, J., Spickermann, J., Schmitt-Hoffmann, A., Heep, M., Denning, D. W. (2006). Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 58: 1198-1207 [Abstract] [Full Text]  
  • Saville, S. P., Lazzell, A. L., Bryant, A. P., Fretzen, A., Monreal, A., Solberg, E. O., Monteagudo, C., Lopez-Ribot, J. L., Milne, G. T. (2006). Inhibition of filamentation can be used to treat disseminated candidiasis.. Antimicrob. Agents Chemother. 50: 3312-3316 [Abstract] [Full Text]  
  • Golan, Y., Wolf, M. P., Pauker, S. G., Wong, J. B., Hadley, S. (2005). Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis. ANN INTERN MED 143: 857-869 [Abstract] [Full Text]